Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: The ENTRANCE study
Klaus Herrlinger(Robert Bosch Hospital), Eduard F. Stange(John Radcliffe Hospital), Klaus Fellermann(Apple (Israel)), Stefanie Howaldt, Mircea Diculescu(Institutul Clinic Fundeni), Bernd Hentsch(MorphoSys (Germany)), Simeon G Stoynov, Barbara Dietrich(MorphoSys (Germany)), R Voiosu, Andrej Petrov(Tokuda Hospital), Aldo Ammendola(MorphoSys (Germany)), H Hartmann(Praxis für Humangenetik), Ulrike Strauch(University Hospital Regensburg), Rosen Nikolov(University Hospital St. Ivan Rilski), Andreas Sturm(German Red Cross), J.‐M. Otte(St. Josef-Hospital), Wolfgang Reindl(Technical University of Munich)
Cited by 74
Related Papers
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
|Journal of Crohn s and Colitis|2018|1.8k
Reduced Paneth cell α-defensins in ileal Crohn's disease
|Proceedings of the National Academy of Sciences|2005|969
NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal α-defensin expression
|Gut|2004|798
A Chromosome 8 Gene-Cluster Polymorphism with Low Human Beta-Defensin 2 Gene Copy Number Predisposes to Crohn Disease of the Colon
|The American Journal of Human Genetics|2006|566
European evidence-based Consensus on the management of ulcerative colitis: Current management
|Journal of Crohn s and Colitis|2008|558